Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

tag:reuters.com,2020:binary_RC2SPK9EA72Y-BASEIMAGE

KIFI

Idaho Falls

Bonneville County

Idaho

United States

European committee takes a second look at Alzheimer's drug and now says it should be approved

Media Bias/Fact Check

NDTV

Independent Media

Gautam Adani

New Delhi

Delhi Division

Delhi

India

European Watchdog Partially Approves New Alzheimer's Drug

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Ad Fontes Media

All Sides

abc News

The Walt Disney Company

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease. The European Commission is expected to decide authorization in the next few months. The com…

News-Press & Gazette Company

Winnipeg Free Press

Winnipeg

Manitoba

Canada

The drug can help slow symptoms in the early stages of the disease. It cannot cure it. And there is a risk of serious side effects. In Germany alone, one million people suffer from Alzheimer's.

Das Medikament kann im frühen Stadium der Krankheit helfen, die Symptome zu verlangsamen. Heilen kann es nicht.  Und es besteht ein Risiko für schwere Nebenwirkungen. Alleine in Deutschland leiden eine Million Menschen an Alzheimer.

EU-Behörde gibt doch noch grünes Licht für Alzheimermittel Leqembi

Sueddeutsche Zeitung

Südwestdeutsche Medien Holding

Munich

Upper Bavaria

Bavaria

Germany

EU authority finally gives green light to Alzheimer's drug Leqembi

The first causal drug for Alzheimer's disease is approved in Europe. Despite side effects and low efficacy, it finally offers hope for real therapies.

In Europa wird das erste kausal wirkende Medikament gegen Alzheimer zugelassen. Trotz Nebenwirkungen und geringer Effizienz birgt es endlich Hoffnung auf echte Therapien.

Neues Alzheimer-Medikament: Das könnte der Anfang vom Ende der Demenz sein

Zeit Online

Holtzbrinck Publishing Group

New Alzheimer's drug: This could be the beginning of the end of dementia

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.  The European Commission is now expected to make a marketing authorization decision in the …

My Mother Lode

European committee takes a second look at Alzheimer’s drug and now says it should be approved

The expert committee of the European Medicines Agency (EMA) recommended this Thursday the approval of lecanemab, the first drug that has been shown to have an effect against Alzheimer's disease in decades, but which is controversial due to its side effects and its high price.Keep reading

El comité de expertos de la Agencia Europea del Medicamento (EMA, por sus siglas en inglés) ha recomendado este jueves la aprobación del lecanemab, el primer fármaco que ha demostrado tener algún efecto contra el alzhéimer en décadas, pero que es controvertido por sus efectos secundarios y su alto precio.Seguir leyendo

Europa recula y recomienda el polémico lecanemab contra el alzhéimer

El Pais

PRISA

Spain

Europe reculates and recommends the controversial lecanemab against the Alzhéimer

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease. The committee had said in July that concerns about the drug’s potential side effects outwei…

Boston Herald

Alden Global Capital

Boston

Suffolk County

Massachusetts

Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall

The drug reduces cognitive impairment caused by the disease by 27%, a clinical trial has revealed. The EU drug regulator had rejected the drug, saying that the risk of severe brain swelling and bleeding did not outweigh its small impact on slowing cognitive decline.

O fármaco reduz em 27% a deterioração cognitiva causada pela doença, revelou um ensaio clínico. O regulador de medicamentos da UE tinha rejeitado o medicamento, dizendo que o risco de inchaço cerebral grave e de hemorragias não superava o seu pequeno impacto no abrandamento do declínio cognitivo

Europa volta atrás e aprova o Lecanemab, um medicamento controverso que mostra potencial contra o Alzheimer

Jornal Expresso

Impresa

Portugal

Europe goes back and approves Lecanemab, a controversial drug that shows potential against Alzheimer's

European Watchdog Partially Approves New Alzheimer's Drug

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics